Europe
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
Dr. Scott Gottlieb estimated that a vaccine for the 5-11-year-old age group could be available by Halloween – in a best-case scenario.
Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Paris-based Sanofi announced its Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit primary or key secondary endpoints.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
French biotech Diaccurate bolstered its oncology and immunology pipeline with the acquisition of a Phase II-ready dual PAM inhibitor from Merck KGaA, Darmstadt, Germany.
Novartis announced that it is discontinuing the trial in kidney transplant patients after conducting an interim analysis from its CIRRUS-1 trial of CFZ533 (iscalimab).
PRESS RELEASES